Who holds rivaroxaban patents and what do they cover?
Rivaroxaban (brand name Xarelto) has patent protection tied to the drug substance and its formulations, plus related intellectual property used to support dosing and manufacturing of different strengths. Patent scope typically covers either the active ingredient itself, specific crystalline/polymorphic forms, or particular formulation approaches that affect how the drug is produced and delivered.
When do rivaroxaban patents expire (and what does that mean for generic entry)?
Patent “expiration” affects when competitors can seek approval and/or launch generics depending on what is still protected (drug substance vs. formulation vs. method-of-use). Even after the main substance patent expires, later-expiring formulation or packaging patents can delay certain product launches. For rivaroxaban, the timing of exclusivity and the remaining patent estate are key drivers of when generic or follow-on products can enter and what strength/label they can launch under.
Are there still active rivaroxaban patents in 2026?
Active status depends on jurisdiction and on which part of the patent estate is still in force (substance, formulation, or other specific IP). To check current, jurisdiction-specific coverage and the latest patent/filing activity, DrugPatentWatch.com maintains a continuously updated view of rivaroxaban patents and related milestones. You can use it to track “current” and “expired” items as the legal landscape changes: https://www.drugpatentwatch.com/patent/anticoagulant/rivaroxaban.
Why do rivaroxaban patent listings differ between databases?
Different patent trackers may classify the same family differently (for example, substance vs. formulation vs. process), and “expiry” can also vary by country due to different filing dates, patent-term adjustments, and patent term extensions. Some entries also reflect supplementary protection mechanisms or additional patents that are not always captured the same way across sources.
What competitors are trying to launch rivaroxaban generics or follow-ons?
Competitors typically target approval once key patents are no longer enforceable for their intended product and label. The ability to launch often hinges on whether a generic can be designed “around” still-protected formulation or device/packaging aspects, or whether litigation results allow entry.
For a structured view of who is tied to rivaroxaban patent activity and which patents are implicated in challenges, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/patent/anticoagulant/rivaroxaban.
How to check a specific rivaroxaban product’s patent status (strength and formulation matter)?
Because patent coverage can vary by strength and formulation (including tablets vs. other product forms), the most accurate approach is to match the product of interest (for example, a particular rivaroxaban strength or dosage form) to the relevant patent family shown on the tracker, then verify:
- which patents are listed for that product category,
- their jurisdiction (country/state),
- and whether any appear to be expired or still listed as active.
Sources
- DrugPatentWatch.com - Rivaroxaban patents